F. Hoffmann-La Roche AG: Data have the power to answer more than one question and enable multiple discoveries, but only if Findable, Accessible, Interoperable, and Reus Switzerland (CH)

Funding Opportunity RFA-DA-20-025 from the NIH Guide for Grants and Contracts. The overall goal of The Step Up for SUD initiative is to advance fundamental discoveries into medicines to treat substance use disorders (SUD) for the benefit of society. The purpose of this funding opportunity is to enhance and accelerate research on drug targets for SUD aiming to expand the range of targets and mechanisms in development for SUD therapies. The initiative will provide both funding and the in-kind access to biomedical product development experts. It will be administered as unique, short-term and nimble funding opportunity to support the confirmatory research in robust drug target validation/invalidation to allow for early decision to either proceed to a next step or stop the projects. At this point, only research projects on potential drug/biologic therapeutics, not diagnostics or devices, will be supported.

Funding Opportunity RFA-NS-19-043 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA.

Funding Opportunity RFA-NS-19-044 from the NIH Guide for Grants and Contracts. The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

Notice NOT-MH-20-006 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-009 from the NIH Guide for Grants and Contracts

Notice NOT-ES-20-003 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-19-506 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) is a serious and burdensome chronic disease that usually onsets in childhood or early adulthood. Recent progress in clinical trials and understanding of T1D pathogenesis and mechanisms have created opportunities to delay the onset and progression of the disease. This supplement is intended to provide resources for the design and conduct of new intervention studies in individuals at early pre-clinical stages of T1D and in individuals with new-onset T1D through the T1D TrialNet network (TrialNet). This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the TrialNet Coordinating Center (TNCC) that is currently supporting the research being performed by TrialNet. The TNCC provides TrialNet with scientific leadership in study design and monitoring, supports the clinical and laboratory testing for the conduct of trials, and supports systems for data collection, processing, biostatistical analyses and administrative operations.

Key contact for gathering requirements from customers (primarily internal), user acceptance, and working with distributed teams to set priorities.
From Resolution Bioscience - Wed, 13 Nov 2019 15:27:00 GMT - View all Kirkland, WA jobs

This facilitator position will be associated with the Data Science Hub, whose mission is to coordinate campus-wide data science resources and expertise, connect…
From University of Wisconsin–Madison - Wed, 13 Nov 2019 00:57:29 GMT - View all Madison, WI jobs

Familiarity with bioinformatic analysis or RNA-seq data, and CRISPR targeting and sequencing analysis is strongly encouraged. Degree and Area of Specialization:
From University of Wisconsin–Madison - Wed, 13 Nov 2019 00:57:22 GMT - View all Madison, WI jobs

Notice NOT-AA-19-031 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-054 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

Funding Opportunity PAR-20-053 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.

Funding Opportunity RFA-AA-20-006 from the NIH Guide for Grants and Contracts. The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimers disease and its related dementias. Recent longitudinal studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimers disease and vascular dementia. Even moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy and frequent alcohol drinking to dementias in aging populations, mechanisms contributing to this relationship are not well understood. With this FOA, we solicitate research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimers disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research.

Notice NOT-OD-20-018 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-20-003 from the NIH Guide for Grants and Contracts. The main goal of this limited competition Funding Opportunity Announcement (FOA) is to continue the state-of the-art biobanking infrastructure and operations for early-stage and experimental clinical trials sponsored by the National Cancer Institute (NCI). The biobanking needs of the following NCI clinical trial programs will be supported: Experimental Therapeutics Clinical Trials Network (ETCTN), and Other NCI-supported early and experimental trials. Currently, this biobanking infrastructure supporting NCI early experimental clinical trials is part of a biobank serving primarily another NCI program, National Clinical Trials Network (NCTN). Through a separate U24 award under this FOA, the NCI aims to separate the existing ETCTN-serving biobanking infrastructure and operation from the current NCTN Biobank. This separated entity will be termed: Early-Phase and Experimental Clinical Trials Biospecimen Bank (also referred to as EET Biobank). Although the EET Biobank and the "parent" NCTN Biobank may be hosted in the same institution, they are expected to become independent operations with separate leaderships. EET Biobank will be responsible for collecting, processing, storing a variety of human specimens from patients with cancer who are participating in NCI-funded ETCTN and other NCI-supported early and experimental clinical trials. The responsibilities of EET Bank will also include maintenance of up-to-date specimen inventory and specimen distribution to qualified NCI-approved trial investigators and research laboratories.

Funding Opportunity PAR-20-051 from the NIH Guide for Grants and Contracts. The NEI Center Core Grant combines three or more Resource and/or Service Cores for a group of R01 investigators to enhance their research, consolidate resources, avoid duplication of efforts, and/or contribute to cost effectiveness by providing a service with lower costs or higher quality than could be attempted for independent projects by several individual Program Directors/Principal Investigators (PD(s)/PI(s)).

Funding Opportunity RFA-DK-19-033 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for Exploratory Centers for Interdisciplinary Research in Benign Urology (P20). A major goal of this program is to build interdisciplinary research teams. The program seeks innovative, high-riskhigh-reward Research Projects that utilize integrative approaches to address questions relevant to benign genitourinary diseases or disorders bringing together investigators with complementary expertise. Studies involving human subjects or tissues and small, innovative, pilot and feasibility clinical studies are encouraged. The following expertise must be included in the proposed Research Project: 1) researchers new to the investigation of benign genitourinary diseases or disorders and 2) clinical urology expertise. Additional expertise may also be included, as needed. In addition to the scientific Research Project, each Exploratory Center must include an Administrative Core with an Educational Enrichment Program. As part of the NIDDK's efforts to expand and enhance benign urology research and the base of urologic researchers, the Exploratory Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54) and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.